Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days

Objective To assess safety, tolerability, pharmacokinetics, and pharmacodynamics of treatment with the selective 11beta-hydroxysteroid dehydrogenase-1 (11beta-HSD1) inhibitor BI 187004 in male and female patients with type 2 diabetes and overweight or obesity. Methods Randomized, double-blind, paral...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianzano, Susanna, Schepers, Cornelia, Wolff, Michael, Heise, Tim, Plum-Moerschel, Leona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811530/
https://www.ncbi.nlm.nih.gov/pubmed/36343645
http://dx.doi.org/10.1055/a-1932-3136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811530/
https://www.ncbi.nlm.nih.gov/pubmed/36343645
http://dx.doi.org/10.1055/a-1932-3136

Ejemplares similares